Grants Search Results

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure. Co-funded by the Rally Foundation for Childhood Cancer Research.

While most childhood cancer patients no longer die from cancer, young adult survivors of childhood cancer face enormously distressing side effects from their life-saving treatments. These include severe sexual and reproductive problems. Currently, no support is available to help educate young adult survivors about how to manage treatment-related sexual problems and fertility-related distress. This project aims to develop and deliver the first sexual health educational intervention for young adult survivors. This research can make a significantly positive impact on the quality of life for thousands of young adult cancer survivors who are struggling and in need of support.

Dr. Aifantis's laboratory is studying T-cell acute lymphoblastic leukemia (T-ALL), a devastating pediatric tumor of the blood. This tumor is characterized by frequent relapses and no cure has been found so far. This lab was one of the first to identify a single gene, Notch1, that is mutated and activated in the majority of T-ALL cases. In this project, Dr. Aifantis studies the way that this gene is regulating disease induction and progression, and tests novel inhibitors of the Notch signaling pathway, hoping that one of them can efficiently suppress T-ALL both in the laboratory and in clinical trials.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

Children with cancer can often be successfully treated with chemotherapy drugs that can unfortunately damage the heart in the process. Development of an effective method to prevent this type of injury while curing the cancer is very important. This consortium's goal is to give children successfully cured of cancer the greatest chance of having a completely healthy life afterwards, free of treatment-related side effects. The study is to determine whether a drug called dexrazoxane, which appears to be safe and effective in adults in preventing chemotherapy-related heart injury, can be similarly safe and effective when used in children. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This grant funded a first year medical student to work in a pediatric oncology research lab for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

Many children with neuroblastoma die of their disease, and treatments sometimes cause lethal side-effects. Dr. Aguilar is studying a family of natural substances called sphingadienes, found in soybeans, that are able to kill colon, prostate and other cancer cell types. While initial studies indicate they may kill neuroblastoma cells too, this study is the first step in exploring sphingadienes as a new treatment option for children with neuroblastoma.

Based on progress to date, Dr. Allen-Rhoades was awarded a new grant in 2014 to fund an optional third year of this fellowship. Osteosarcoma is a bone cancer that affects children, adolescents and young adults. Patients have better survival if the cancer has not spread to other parts of the body. This project aims to develop a blood test that can detect the cancer and determine if it has spread to other areas. This test will be more sensitive and easier to use than current methods, and will ultimately help improve the survival of children with osteosarcoma.

Based on progress to date, Dr. Annesley, Tap Cancer Out St. Baldrick’s Fellow, was awarded a new grant in 2014 to fund an optional third year of this fellowship. Acute myeloid leukemia (AML) is a malignant cancer of the white blood cells. Each year in the United States, approximately 10,000 adults and 1,000 children are diagnosed with AML. Only about 50% of these patients will be cured with current chemotherapy. Recently, mutations of genes have been shown to contribute to the development of AML, such as the FLT3/ITD mutation. Another mutation, Wilms tumor 1 (WT1) has been demonstrated in about 10% of patients with AML, but its effect on the development of leukemia is not well understood. WT1 and FLT3/ITD mutations can occur together, and patients with both mutations have dismal survival rates of 15%. This project attempts to prove that these two mutations can work together and may contribute to the formation of leukemia. It also attempts to show that mutations of WT1 cause cells to function abnormally, directly contributing to the development of leukemia. Early research shows that cells with WT1 mutations grow faster and more aggressively. Researchers have created the first model to study the interaction between FLT3/ITD and WT1 mutations. Ultimately, if WT1 mutations are shown to contribute to the formation of leukemia, the development of a drug that interferes with WT1 could improve cure rates in patients with AML.

This grant recognizes the partnership with Tap Cancer Out, a jiu-jitsu based 501(c)(3) nonprofit raising awareness and funds for cancer fighting organizations on behalf of the grappling community.